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Private Sector
Opportunities
Abound with
the Arrival of

As preparatory
work and preliminary
construction progresses on
the National Bio and Agrodefense Facility site north
of Kansas State University,
the opportunities for the
private sector continue to
grow.

NBAF
The Pre-Decisional Draft of NBAF

The arrival of the
$650 million Department
of Homeland Security
facility will foster local and
regional development, university leaders say,
and may create new partnerships for K-State,
the Manhattan community and animal
health companies both inside and outside the
Kansas City Animal Health Corridor.
“Only time will tell how many and what
kind of private sector opportunities will
arise because of NBAF,” said Ron Trewyn,
K-State’s vice president for research. “But
I think it’s pretty clear with all the Animal
Health Corridor companies that are in the
area that there is great potential.”
When the Department of Homeland
Security named Manhattan as the official
site for NBAF in early 2009, Trewyn was
amazed at the number of pharmaceutical
companies that started contacting K-State,
the Manhattan Chamber of Commerce and
the Kansas Department of Commerce. While
some of the larger companies were interested
in expanding to the Manhattan area, other
smaller animal health companies talked
about completely relocating to the area.
Companies of all sizes were interested
in opportunities both at K-State and
in the Animal Health Corridor region,
which stretches from Manhattan, Kan.,
to Columbia, Mo. This region is already a
hotspot for animal health — containing onethird of the world’s marketplace for animal
health companies and including more than
13,000 employees — but the addition of
NBAF makes it even more appealing.
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Perspectives

“Some of the companies in this region
are expressing interest in what might be
available near the NBAF site in Manhattan,”
Trewyn said. “But we’re also being contacted
by animal health companies that aren’t
currently located in the Animal Health
Corridor.”
With construction of the lab itself slated
to begin in early 2012, it’s likely that more
companies will be attracted to the area.
While there is limited land close to campus
for companies to build, Trewyn noted that
space is available throughout the Manhattan
area. He pointed to the 25-acre K-State
Research Park on Manhattan Avenue east
of the NBAF site as a potential place for
companies to locate.
While negotiations with companies are
still in the early stages, the arrival of NBAF
will also give K-State the ability to compete
for science or policy-related programs,
particularly related to zoonotic and animal
diseases. NBAF’s emphasis on animal
vaccinations, as well as new antibiotic and
antiviral treatments, will help attract animal
health companies that focus on infectious
diseases or diagnoses.
“When it comes right down to it,
Manhattan is going to become the epicenter
for the world’s animal health,” said Daniel
Thomson, who is the Jones professor of
production medicine and epidemiology for
the K-State College of Veterinary Medicine.
His research group has used K-State facilities

to develop the E. coli O157:
H7 vaccine for cattle.
Thomson sees huge
potential for animal health
private industry because
NBAF and K-State’s
Biosecurity Research
Institute will provide new
biosafety level 3 and level
4 laboratories, where
scientists can research
pathogens such as foot-andmouth disease, swine fever

and anthrax.
“I think it will attract some of the
best and brightest minds to work in these
facilities,” Thomson said. “The collaboration
that K-State will be able to do with those
facilities will help K-State recruit the best
and brightest students as well.”
The development of animal vaccines
will be particularly important, Thomson
said. When researchers are able to develop
vaccines, they’ll need industry partners to
produce the vaccines. In many cases, it makes
sense for animal health and pharmaceutical
companies to be geographically close to the
researchers.
“When I look at NBAF and K-State as
a whole, the way I describe Manhattan is
the front gate to the west,” Thomson said.
“Our function at Kansas State University is
to be the gate — that ability to scientifically
and independently review the things that are
coming from the industry to improve the
health and performance of animals.
“We’re at the point in time where
industry and agriculture shake hands,”
Thomson said.

By Jennifer Torline, Communications and Marketing
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About the

B

iocontainment facilities are
classified by the Centers
for Disease and Prevention
Control and the National Institutes
of Health into four distinct levels,
depending on the nature of the research
and the biological agents that will be
used in the laboratory. These levels
are Biosafety Level 1, 2, 3 or 4, and are
normally designated as BSL-1, BSL-2, BSL3 and BSL-4.
Biosafety level 1 basically covers
organisms that are not normally
hazardous to healthy adults. Biosafety
level 2 covers organisms and biological
materials that pose moderate hazards
to adults and personnel. These
laboratories also have limited access
and documented procedures for
handling biological materials. Biosafety
level 3 designates work with biological
materials that could cause serious illness
— including death — to humans if not
handled properly. Biological materials
falling into this category include
pathogens like the West Nile virus. The

Biosecurity Research Institute

highest level of biosafety is BSL-4, which
involves work with biological materials
where vaccines are not currently
available and which require workers to
wear full hazmat-like positive pressure
suits with self-contained air supplies.

site inspections by the Institutional
Biosafety Committee and University
Research Compliance Office for facility
compliance, as well as for appropriate
documentation for laboratory policies
and procedures.

The Biosecurity Research Institute will
not be working with any BSL-4 biological
materials. The BRI is a BSL-3 and BSL3Ag facility, the latter an enhanced and
specialized form of BSL-3 for working
with livestock. BSL-3Ag incorporates
almost all the same construction features
of a BSL-4 facility and must meet specific
construction standards set by USDA for
the rooms to be primary containment
barriers. However, the self-contained
“space suits” are not required.

In order to work with more hazardous
biological materials, additional
external inspections must be made by
organizations such as the CDC or the U.S.
Department of Agriculture. This is the
case with the most rigorously regulated
biological materials, which are termed
“select agents.” Facility inspections are
done for each specific project involving
a select agent to ensure that the facility
is configured appropriately, that the
support staff are trained to safely
handle the specific select agent, that
the experimental plans and security
measures for the select agents are
appropriate and documented, and
that the select agent can be used in a
safe and secure manner for the facility
personnel and surrounding community.

At K-State all laboratories are
inspected by the Environmental
Health and Safety office. Those using
biological materials must have their
activities approved by the Institutional
Biosafety Committee. These approvals
follow a prescribed process and include
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Biosecurity Research Institute Advisory Board

Guy Palmer, DVM, Ph.D.

Jan Sargeant, DVM, M.S., Ph.D

[

Alfonso Torres, DVM, M.S., Ph.D.

Dr. Guy Palmer is the Creighton chair and
“ The Biosecurity Research Institute provides a unique resource needed to discover
director of the Washington State University
and fully develop innovative approaches to control infectious diseases. While clearly
School for Global Animal Health and the Regents professor of pathology and infectious
providing new opportunities for K-State faculty and affiliated scientists, the BRI is also
diseases. Dr. Palmer’s goal is to improve the
a regional and national resource that can catalyze research to improve both livestock
control of animal diseases with direct impact
productivity and public health.
on human health and well‐being. Within this
focus, he has led collaborative infectious diseases research programs in southern and eastern Africa, the Middle East, and Latin America, where he currently directs a multi‐institutional research effort studying genetic change in microbial pathogens and the risk for shifts in disease pattern and emergence.

]

”

Dr. Jan Sargeant is the director of the Centre for Public Health and Zoonoses at the University of Guelph in Ontario, Canada. Dr. Sargeant has performed research in

[

areas of agri‐food
“ The Biosecurity Research Institute at Kansas State University is unique in its ability to support high
public health, policy
containment infectious disease research activities from basic discovery research through live animal and plant
research in microexperiments. The diversity of approaches also leads to scientists from multiple disciplines working together
bial food safety,
and networking. This dynamic research environment and innovative research facility will produce research
perception of risk
results that will lead to improved human and animal health in the U.S. and internationally.
of gastrointestinal
illnesses, food and
water safety, and the role of veterinary medicine in public health. She is currently developing a research agenda focused on policy and outcome evaluation issues
in the prevention of zoonotic disease.

”

[
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Dr. Alfonso Torres is the
“ The Biosecurity Research Institute’s current capability provides a significant jumpstart for Kansas
associate dean for public policy
State University to work in this important field ahead of the construction and activation of the National
in the College of Veterinary
Bio and Agro-defense Facility, placing K-State as the leading U.S. academic institution in the field of
Medicine at Cornell University.
research on the most important pathogens that affect the health of plants, animals and people.
Prior to his current position,
Dr. Torres served as the deputy
administrator for Veterinary Services of USDA APHIS and U.S. chief veterinary officer and delegate to the World Organization for Animal Health. Dr. Torres was the
director of the USDA’s Plum Island Animal Disease Center on Plum Island, N.Y., from 1996 to 1999, following three years as chief of the Foreign Animal Disease Diagnostic Laboratory there. Prior to his service at USDA, Dr. Torres held academic positions at the National University of Colombia, the University of Nebraska‐Lincoln, and Cornell
University. Between academic experiences, Dr. Torres also worked in research and development and marketing of veterinary biologics and diagnostics with two large
multinational corporations.
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